Tc-99m SPECT sestamibi for the measurement of infarct size

Raymond J. Gibbons

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


There are a variety of approaches to assess the efficacy of reperfusion therapy, and myocardial protection, in acute myocardial infarction. This review summarizes the available evidence validating the use of technetium-99m sestamibi single-photon emission computed tomography (SPECT) for this purpose. Multiple lines of evidence have validated its clinical utility. SPECT sestamibi infarct size has been used as an endpoint in multiple randomized clinical trials. A smaller number of clinical trials have used both early and later imaging with SPECT sestamibi to assess myocardium at risk and myocardial salvage. SPECT sestamibi has a number of limitations which must be recognized. Nevertheless, SPECT sestamibi infarct size is a well-validated measurement with a long track record of performance as an endpoint in multicenter, randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)321-331
Number of pages11
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Issue number3-4
StatePublished - Sep 2011


  • acute myocardial infarction

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Tc-99m SPECT sestamibi for the measurement of infarct size'. Together they form a unique fingerprint.

Cite this